IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $12.51 million. The enterprise value is $4.53 million.
| Market Cap | 12.51M |
| Enterprise Value | 4.53M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 3.43 million shares outstanding. The number of shares has increased by 26.04% in one year.
| Current Share Class | 3.43M |
| Shares Outstanding | 3.43M |
| Shares Change (YoY) | +26.04% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 35.88% |
| Owned by Institutions (%) | 3.20% |
| Float | 2.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.51 |
| Forward PS | 2.29 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.52, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.52 |
| Quick Ratio | 1.75 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -265.83 |
Financial Efficiency
Return on equity (ROE) is -217.23% and return on invested capital (ROIC) is -130.59%.
| Return on Equity (ROE) | -217.23% |
| Return on Assets (ROA) | -80.33% |
| Return on Invested Capital (ROIC) | -130.59% |
| Return on Capital Employed (ROCE) | -184.54% |
| Weighted Average Cost of Capital (WACC) | 12.95% |
| Revenue Per Employee | $51,667 |
| Profits Per Employee | -$228,159 |
| Employee Count | 69 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 0.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.19% in the last 52 weeks. The beta is 1.54, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | -88.19% |
| 50-Day Moving Average | 5.36 |
| 200-Day Moving Average | 15.39 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 2,511,142 |
Short Selling Information
The latest short interest is 325,222, so 9.49% of the outstanding shares have been sold short.
| Short Interest | 325,222 |
| Short Previous Month | 89,416 |
| Short % of Shares Out | 9.49% |
| Short % of Float | 14.80% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.57 million and -$15.74 million in losses. Loss per share was -$6.99.
| Revenue | 3.57M |
| Gross Profit | 1.30M |
| Operating Income | -15.68M |
| Pretax Income | -15.74M |
| Net Income | -15.74M |
| EBITDA | -15.41M |
| EBIT | -15.68M |
| Loss Per Share | -$6.99 |
Balance Sheet
The company has $8.12 million in cash and $139,000 in debt, with a net cash position of $7.98 million or $2.33 per share.
| Cash & Cash Equivalents | 8.12M |
| Total Debt | 139,000 |
| Net Cash | 7.98M |
| Net Cash Per Share | $2.33 |
| Equity (Book Value) | 8.49M |
| Book Value Per Share | 3.14 |
| Working Capital | 7.32M |
Cash Flow
In the last 12 months, operating cash flow was -$14.81 million and capital expenditures -$81,000, giving a free cash flow of -$14.89 million.
| Operating Cash Flow | -14.81M |
| Capital Expenditures | -81,000 |
| Depreciation & Amortization | 275,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -14.89M |
| FCF Per Share | -$4.35 |
Margins
| Gross Margin | 36.55% |
| Operating Margin | -439.94% |
| Pretax Margin | -441.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.04% |
| Shareholder Yield | -26.04% |
| Earnings Yield | -125.88% |
| FCF Yield | -119.04% |
Analyst Forecast
The average price target for IceCure Medical is $30.50, which is 735.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.50 |
| Price Target Difference | 735.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 97.68% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 4, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jun 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
IceCure Medical has an Altman Z-Score of -9.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.2 |
| Piotroski F-Score | 3 |